Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 12 May 2026
All 20 smoldering myeloma patients had deep responses after one-time infusion
Read Full NewsThe phase 3 HARMONIA trial will evaluate whether a muscle- and CNS-targeted antisense conjugate improves function across multiple systems in patients with myotonic dystrophy type 1.
New data from the 2026 AANEM Annual Meeting showed zilucoplan delivered via autoinjector was bioequivalent to the pre-filled syringe and was well tolerated when self-administered by patients with generalized myasthenia gravis.
The ongoing phase 3 study is enrolling approximately 180 adults across more than 13 countries, with topline results expected in mid-2027.
EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.
Phase 3 trials EMNERGIZE and EMVIGORATE will evaluate the efficacy and safety of intravenous empasiprubart in adults with chronic inflammatory demyelinating polyradiculoneuropathy.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
Lessons From 10,000 Organ Transplants, With Ari Cohen, MD
1.
BMTs that are "half-matched" are effective in treating severe sickle cell disease.
2.
The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.
3.
According to JAMA, women who have false-positive mammogram results are at a higher risk of developing breast cancer over time.
4.
Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patients
5.
What Caused a Man to Develop Friable Bleeding Nodules on His Arms and Hips?
1.
Exploring the Benefits of Flexible Sigmoidoscopy: A Revolutionary Way to Detect Colorectal Cancer
2.
Therapeutic Advances in Tumor Calcium-Signaling Modulation
3.
Thyroidectomy & Survival: Highlights from ASCO 2025 and Current U.S. Findings
4.
Bone Marrow Regeneration in Hematologic Recovery
5.
HCC Codes in Oncology: Care Optimization in Plexiform Neurofibroma Management
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
4.
Evidence-Based Oncology
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge